Trial Profile
A randomised, double blind phase I study to assess the safety, pharmacokinetics and pharmacodynamics of single and 14 days dosing with two vaginal microbicide formulations containing either Darunavir, or Dapivirine and Darunavir
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Dapivirine (Primary) ; Darunavir (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms DAPIDAR v2.0
- 01 Jul 2015 Accrual to date is 104% according to United Kingdom Clinical Research Network record
- 28 May 2015 Accrual to date is 95% according to United Kingdom Clinical Research Network record
- 14 May 2015 Accrual to date is 50% according to United Kingdom Clinical Research Network record